ProAssurance has reported second-quarter 2025 net income of $21.9 million and operating income of $26.8 million.
For the first half of the year, net income totaled $16.1 million and operating income was $33.6 million.
The company said quarterly net results included $4.8 million in non‑operating items. Net premiums written in the medical professional liability (MPL) business were $135.9 million, representing more than 95% of the specialty P&C segment.
While MPL premiums were steady, other lines in the segment saw declines. Workers’ compensation insurance segment net premiums written increased by $1.4 million.
In the first quarter of 2025, ProAssurance reported a net loss of $5.8 million and operating income of $6.8 million. MPL premiums for that quarter totaled $204.5 million, while workers’ compensation premiums rose by $1.3 million.
Chief executive officer Ned Rand (pictured above) said the company’s experience in MPL supports its belief that targeted actions in a cyclical market can deliver sustainable results over time.
“The quarter again illustrated benefits from our focus on ongoing actions to achieve sustained profitability, including price adequacy, disciplined underwriting and cost management, and we expect to see further progress in coming quarters,” Rand said.
Specialty P&C renewal premium rates rose 10% in the quarter, contributing to a cumulative premium change of more than 70% since 2018 in the MPL market. Retention for the specialty P&C segment was 81%, including 82% for the standard physicians MPL portfolio. The company said it continues to decline new and renewal business that does not meet pricing standards for the current MPL loss environment.
The company’s strategy of pursuing steady renewal rate increases in the specialty P&C business has included recent hikes of 13% in certain quarters, part of a multi‑year effort to counter rising claim severity in the MPL market. Since 2018, cumulative rate changes have surpassed 65%, aimed at restoring margins in an increasingly challenging liability environment.
The consolidated non‑GAAP combined ratio improved 9.5 percentage points from the second quarter of 2024. The Specialty P&C segment’s non‑GAAP combined ratio improved 11.6 percentage points year over year, largely due to favorable prior‑year reserve development.
Net investment income rose 6%, driven by higher average book yields and increased average investment balances. Earnings from limited partnership investments reflected lower market valuations in late 2024 and early 2025.
Book value per share was $24.80 as of June 30, up from $23.49 at the end of 2024. Non‑GAAP adjusted book value per share was $27.07, compared with $26.86 at year‑end.
A few months ago, ProAssurance announced it had entered into a definitive agreement to be acquired by The Doctors Company for approximately $1.3 billion in cash, at $25 per share. The deal represents a 60.9% premium to its closing price the day before the announcement and is expected to close in the first half of 2026.
“Joining forces with The Doctors Company through the transaction we announced in March will allow our organizations to continue to serve today’s healthcare providers with the necessary scale and breadth of capabilities,” Rand said.
What are your thoughts on this story? Please feel free to share your comments below.
